Invenomic Capital Management LP Has $9.62 Million Stock Holdings in American Vanguard Co. (NYSE:AVD)

Invenomic Capital Management LP raised its position in American Vanguard Co. (NYSE:AVD) by 256.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 876,708 shares of the basic materials company’s stock after buying an additional 631,070 shares during the quarter. Invenomic Capital Management LP owned 3.05% of American Vanguard worth $9,617,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC grew its holdings in American Vanguard by 492.4% in the 4th quarter. CWM LLC now owns 2,340 shares of the basic materials company’s stock valued at $26,000 after buying an additional 1,945 shares in the last quarter. Gladius Capital Management LP bought a new stake in shares of American Vanguard during the 4th quarter valued at $37,000. Tower Research Capital LLC TRC lifted its position in shares of American Vanguard by 240.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,885 shares of the basic materials company’s stock valued at $76,000 after acquiring an additional 4,863 shares during the period. Bfsg LLC bought a new stake in shares of American Vanguard during the 4th quarter valued at $98,000. Finally, WINTON GROUP Ltd bought a new stake in shares of American Vanguard during the 3rd quarter valued at $119,000. 79.04% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Steven D. Macicek purchased 8,500 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $9.01 per share, with a total value of $76,585.00. Following the completion of the purchase, the director now owns 10,044 shares in the company, valued at approximately $90,496.44. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Steven D. Macicek purchased 8,500 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $9.01 per share, with a total value of $76,585.00. Following the completion of the purchase, the director now owns 10,044 shares in the company, valued at approximately $90,496.44. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Ulrich Trogele purchased 18,200 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was bought at an average cost of $8.75 per share, with a total value of $159,250.00. Following the purchase, the insider now owns 209,876 shares of the company’s stock, valued at approximately $1,836,415. The disclosure for this purchase can be found here. Insiders own 10.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. Loop Capital upped their target price on American Vanguard from $19.00 to $20.00 and gave the company a “buy” rating in a research report on Monday, April 15th. StockNews.com downgraded American Vanguard from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Finally, Roth Mkm upped their price objective on American Vanguard from $13.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. One investment analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, American Vanguard currently has an average rating of “Moderate Buy” and an average price target of $18.00.

American Vanguard Trading Down 0.7 %

American Vanguard stock traded down $0.06 during trading hours on Monday, hitting $8.61. The stock had a trading volume of 85,565 shares, compared to its average volume of 217,134. The company has a quick ratio of 1.12, a current ratio of 2.29 and a debt-to-equity ratio of 0.50. The stock has a market cap of $240.99 million, a price-to-earnings ratio of 32.85 and a beta of 0.95. American Vanguard Co. has a one year low of $8.41 and a one year high of $18.31. The business’s 50 day simple moving average is $10.62 and its 200-day simple moving average is $10.74.

American Vanguard (NYSE:AVD) last posted its earnings results on Thursday, May 9th. The basic materials company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.08 by $0.01. The firm had revenue of $135.14 million during the quarter, compared to the consensus estimate of $141.20 million. American Vanguard had a return on equity of 2.20% and a net margin of 1.22%. During the same period last year, the company earned $0.07 earnings per share. On average, equities analysts predict that American Vanguard Co. will post 0.44 EPS for the current fiscal year.

About American Vanguard

American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally. It manufactures and formulates chemicals, including insecticides, fungicides, herbicides, soil health, plant nutrition, molluscicides, growth regulators, soil fumigants, and biorationals in liquid, powder, and granular forms for crops, turf and ornamental plants, and human and animal health protection.